Management of hypoglycemia in older adults with type 2 diabetes

References

• United States Census Bureau [Internet]. Demographic turning points for the United States: population projection for 2020 to 2060; 2018 [cited 2018 Mar 21]. Available from: https://www.census.gov/content/dam/Census/library/publications/2018/demo/P25_1144.pdf
   Google Scholar
• American Diabetes Association [Internet]. Statistics about diabetes; 2017 [cited 2018 Mar 15]. Available from: http://www.diabetes.org/diabetes-basics/statistics/
   Google Scholar
• Centers for Disease Control and Prevention [Internet]. National diabetes statistics report; 2017 [cited 2018 Mar 18]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Dunning T, Rodriguez-Manas L. Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol. 2015;3:275–285.
   PubMed Web of Science ®Google Scholar
• Huang ES, Laiteerapong N, Liu JY, et al. Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med. 2014;174:251–258.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic cost of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–1046.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among medicare beneficiaries, 1999 to 2011. JAMA Intern Med. 2014;174:1116–1124.
   PubMed Web of Science ®Google Scholar
• Goyal R, Sura S, Mehta H. Direct medical costs of hypoglycemia hospitalizations in the United States. Poster session presented at: ISPOR 20th Annual European Congress; 2017 Nov 4–8; Glasglow, Scotland.
   Google Scholar
• Abdelhafiz AH, Rodriguez-Manas L, Morley JE, et al. Hypoglycemia in older people - a less well recognized risk factor for frailty. Aging Dis. 2015;6:156–167.
   PubMed Web of Science ®Google Scholar
• Heller S. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2017;40:155–157.
   PubMed Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395.
   PubMed Web of Science ®Google Scholar
• Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the endocrine society, JDRF International, the Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D exchange. Diabetes Care. 2017;40:1622–1630.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Older adults: standards of medical care in diabetes. Diabetes Care. 2018;41:S119–S125.
   PubMed Web of Science ®Google Scholar
• Klonoff C, Parkes JL, Kovatchev BP, et al. Investigation of the accuracy of 18 marketed blood glucose monitors. Diabetes Care. 2017;41:1681–1688.
   Web of Science ®Google Scholar
• Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18:S3–S13.
   PubMed Web of Science ®Google Scholar
• Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–374.
   PubMed Web of Science ®Google Scholar
• Rosman P, Freeman J, Aschemeyer J, et al. Continuous glucose monitoring assessment of glucose variability with liraglutide add-on or substitution in T2DM during 24 hour and 3 hour time-periods. Jacobs J Diabetes Endocrinol. 2015;1:e009.
   Google Scholar
• Ruedy KJ, Parkin CG, Riddlesworth TD, et al. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138–1146.
   PubMedGoogle Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract. 2017;23:207–238.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Glycemic targets: standards of medical care in diabetes. Diabetes Care. 2018;41:S55–S64.
   PubMed Web of Science ®Google Scholar
• Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology - continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:3922–3937.
   PubMed Web of Science ®Google Scholar
• Forlenza GP, Argento NB, Laffel LM. Practical considerations on the use of continuous glucose monitoring in pediatrics and older adults and nonadjunctive use. Diabetes Technol Ther. 2017;19:S13–S20.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Peters AL, Hessler D. The impact of real-time continuous glucose monitoring in patients 65 years and older. J Diabetes Sci Technol. 2016;10:892–897.
   PubMedGoogle Scholar
• Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.
   PubMed Web of Science ®Google Scholar
• Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–1640.
   PubMed Web of Science ®Google Scholar
• Bruen D, Delaney C, Florea L, et al. Glucose sensing for diabetes monitoring: recent developments. Sensors (Basel). 2017;17:e1866.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest. 2006;116:1470–1473.
   PubMed Web of Science ®Google Scholar
• Cantlay A, Glyn T, Barton N. Polypharmacy in the elderly. InnovAiT. 2016;92:69–77.
   Google Scholar
• Hope SV, Taylor PJ, Shields BM, et al. Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Prim Care Diabetes. 2018;12:139–146.
   PubMed Web of Science ®Google Scholar
• Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005–2011. Diabetes Care. 2016;39:363–370.
   PubMed Web of Science ®Google Scholar
• Yun JS, Ko SH, Ko SH, et al. Cardiovascular disease predicts severe hypoglycemia in patients with type 2 diabetes. Diabetes Metab J. 2015;39:498–506.
   PubMed Web of Science ®Google Scholar
• Munshi M. [Internet]. Treatment of type 2 diabetes mellitus in the older patient; 2018 [cited 2018 Jun 21]. Available from: https://www.uptodate.com/contents/treatment-of-type-2-diabetes-mellitus-in-the-older-patient
   Google Scholar
• Advance Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–139.
   PubMed Web of Science ®Google Scholar
• Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J. 2016;40:423–432.
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
   PubMed Web of Science ®Google Scholar
• Sardar P, Udell JA, Chatterjee S, et al. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;4:e001577.
   PubMed Web of Science ®Google Scholar
• Thorpe CT, Gellad WF, Good CB, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care. 2015;38:588–595.
   PubMed Web of Science ®Google Scholar
• Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose-lowering agents: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18:135–141.
   PubMed Web of Science ®Google Scholar
• Lipska KJ, Krumholz H, Soones T, et al. Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. JAMA. 2016;315:1034–1045.
   PubMed Web of Science ®Google Scholar
• Cahn A, Raz I, Kleinman Y, et al. Clinical assessment of individualized glycemic goals in patients with type 2 diabetes: formulation of an algorithm based on a survey among leading worldwide diabetologists. Diabetes Care. 2015;38:2293–2300.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2018;41:S73–S85.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–2701.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes. Diabetes Care. 2017;40:S64–S74.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S90–S102.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.
   PubMed Web of Science ®Google Scholar
• White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:668–673.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579–1588.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385:2067–2076.
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals America Inc [Internet]. NESINA® (alogliptin) tablets, for oral use: prescribing information; 2016 [cited 2018 Mar 13]. Available from: https://general.takedapharm.com/NESINAPI
   Google Scholar
• AstraZeneca Pharmaceuticals LP [Internet]. ONGLYZA® (saxagliptin) tablets, for oral use: prescribing information; 2017 [cited 2018 Mar 13]. Available from: https://www.azpicentral.com/onglyza/pi_onglyza.pdf#page=1
   Google Scholar
• Leiter LA, Teoh H, Braunwald E, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care. 2015;38:1145–1153.
   PubMed Web of Science ®Google Scholar
• Bethel MA, Engel SS, Green JB, et al. Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS). Diabetes Care. 2017;40:494–501.
   PubMed Web of Science ®Google Scholar
• Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57:2011–2019.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Paldanius PM, Ayyagari R, et al. Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment. Diabetes Ther. 2016;7:439–454.
   PubMed Web of Science ®Google Scholar
• Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12:164–174.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2013;10:289–301.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S [Internet]. VICTOZA® (liraglutide) injection, for subcutaneous use: prescribing information; 2017 [cited 2018 Mar 18]. Available from: http://www.novo-pi.com/victoza.pdf
   Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Design and baseline characteristics of participants in the researching cardiovascular events with a weekly INcretin in diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42–49.
   PubMed Web of Science ®Google Scholar
• Athauda D, Foltynie T. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today. 2016;21:802–818.
   PubMed Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2018. Epub ahead of print. DOI:10.1161/CIRCULATIONAHA.118.037778
   Web of Science ®Google Scholar
• Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37:1526–1534.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:e4–e5.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc [Internet]. JARDIANCE® (empagliflozin) tablets, for oral use: prescribing information; 2018 [cited 2018 Dec 15]. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101:157–166.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceuticals Inc [Internet]. INVOKANA® (canagliflozin) tablets, for oral use: prescribing information; 2018 [cited 2018 Dec 15]. Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf
   Google Scholar
• Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137:323–334.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. Epub ahead of print. DOI:10.1056/NEJMoa1812389
   Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018;393:P31–P39.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71:2628–2639.
   PubMed Web of Science ®Google Scholar
• Holstein A, Hammer C, Hahn M, et al. Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf. 2010;9:675–681.
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Expert Panel on Care of Older Adults with Diabetes Mellitus. Guidelines abstracted from the American Geriatrics Society guidelines for improving the care of older adults with diabetes mellitus: 2013 update. J Am Geriatr Soc. 2013;2013(61):2020–2026.
   Web of Science ®Google Scholar
• World Health Organization [Internet]. Guidelines on second- and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus; 2018 [cited 2018 Mar 16]. Available from: http://apps.who.int/iris/handle/10665/272433
   Google Scholar
• Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723–732.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Harris SB, Baron H, et al. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units/mL versus 100 units/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care. 2018;41:1672–1680.
   PubMed Web of Science ®Google Scholar
• Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 u/mL versus glargine 100 u/mL in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–867.
   PubMed Web of Science ®Google Scholar
• Yale JF, Aroda VR, Charbonnel B, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: a patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2018. Epub ahead of print. DOI:10.1016/j.diabet.2018.10.002
   Web of Science ®Google Scholar
• Greco D, Pisciotta M, Gambina F, et al. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes. 2010;118:215–219.
   PubMed Web of Science ®Google Scholar
• Brodovicz KG, Mehta V, Zhang Q, et al. Association between hypoglycemia and inpatient mortality and length of hospital stay in hospitalized, insulin-treated patients. Curr Med Res Opin. 2013;29:101–107.
   PubMed Web of Science ®Google Scholar
• Hirschman KB, Bixby MB. Transitions in care from the hospital to home for patients with diabetes. Diabetes Spectr. 2014;27:192–195.
   PubMedGoogle Scholar
• LaManna JB, Bushy A, Norris AE, et al. Early and intermediate hospital-to-home transition outcomes of older adults diagnosed with diabetes. Diabetes Educ. 2016;42:72–86.
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality [Internet]. Care coordination measures atlas update. Chapter 2. What is care coordination?; 2014 [cited 2018 Mar 15]. Available from: https://www.ahrq.gov/professionals/prevention-chronic-care/improve/coordination/atlas2014/chapter2.html
   Google Scholar
• Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-performance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310:1051–1059.
   PubMed Web of Science ®Google Scholar
• Pan CC, Kung PT, Chiu LT, et al. Patients with diabetes in pay-for-performance programs have better physician continuity of care and survival. Am J Manag Care. 2017;23:e57–e66.
   PubMed Web of Science ®Google Scholar
• Mendelson A, Kondo K, Damberg C, et al. The effects of pay-for-performance programs on health, health care use, and processes of care: a systematic review. Ann Intern Med. 2017;166:341–353.
   PubMed Web of Science ®Google Scholar